Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab and Nivolumab vs Lomustine in Recurrent Glioblastoma
NCT06325683Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Nov 2024
- Primary completion
- Jul 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab in glioblastoma (GBM), sponsored by National Cancer Institute. Started Nov 2024; status: suspended.
02
Drugs
relatlimabnivolumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06325683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325683.